Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)
The Hepato-protective Effect of Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)
Sponsor: Rehab Werida
A PHASE4 clinical study on Nonalcoholic Fatty Liver Disease and Type 2 Diabetes, this trial is completed. The trial is conducted by Rehab Werida and has accumulated 7 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Mar 2025 — Present [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Sep 2024 — Mar 2025 [monthly]
Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE4
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE4
-
Oct 2023 — Mar 2024 [monthly]
Recruiting PHASE4
▶ Show 2 earlier versions
-
Nov 2022 — Oct 2023 [monthly]
Recruiting PHASE4
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE4
First recorded
May 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Rehab Werida
- University of Alexandria
For direct contact, visit the study record on ClinicalTrials.gov .